预防性阿司匹林剂量与子痫前期
该全国性队列纳入瑞典2017年1月至2020年12月分娩(≥22周)且孕期使用低剂量阿司匹林(75~160 mg)的13 828名女性,比较150~160 mg组(4687人,33.9%)与75 mg组(9141人,66.1%)的子痫前期和产后出血风险。150~160 mg组子痫前期443例(9.5%)vs 75 mg组812例(8.9%),校正RR 1.07(95%CI 0.93-1.24);产后出血326例(6.9%)vs 581例(6.4%),校正RR 1.08(95%CI 0.90-1.30),均无显著差异。作者认为两种剂量均可作为预防子痫前期的合理选择,但仍需大型随机试验。
要点
- 瑞典全国队列13 828名孕妇中,150~160 mg阿司匹林组子痫前期9.5%(443例)vs 75 mg组8.9%(812例),校正RR 1.07(95%CI 0.93-1.24),无显著差异。
- 产后出血(>1000 mL)150~160 mg组6.9%(326例)vs 75 mg组6.4%(581例),校正RR 1.08(95%CI 0.90-1.30),两组风险相似。
- 队列中76.9%(10 635人)至少配取2次低剂量阿司匹林处方,150~160 mg组占33.9%(4687人),75 mg组占66.1%(9141人)。
- 作者认为,使用阿司匹林预防子痫前期时,两种剂量均可作为合理选择;但仍需大型随机试验研究孕期阿司匹林剂量。
适用人群与场景
- 瑞典2017年1月至2020年12月分娩(孕周≥22周)且孕期使用低剂量阿司匹林(75~160 mg)的女性,共13 828人;平均(SD)年龄33.0(5.5)岁,初产妇3003人(21.7%)。
研究设计与关键结果
- 全国性队列研究,纳入13 828名孕期使用低剂量阿司匹林(75~160 mg)并分娩(≥22周)的女性,比较150~160 mg组(4687人,33.9%)与75 mg组(9141人,66.1%)。
- 主要结局子痫前期(出院时母体分娩记录诊断):150~160 mg组443例(9.5%)vs 75 mg组812例(8.9%),校正RR 1.07(95%CI 0.93-1.24)。
- 主要安全结局产后出血(分娩后出血>1000 mL):150~160 mg组326例(6.9%)vs 75 mg组581例(6.4%),校正RR 1.08(95%CI 0.90-1.30)。
- 采用双重稳健逆概率加权回归调整模型控制背景特征,估计相对风险(RR)及95%CI。
证据类型、等级与局限
- 证据类型:全国性队列研究。
- 作者指出,仍需大型随机试验研究孕期阿司匹林剂量。
对床旁实践的改变
- 作者认为,使用阿司匹林预防子痫前期时,150~160 mg与75 mg两种剂量均可作为合理选择。
- 作者建议,仍需大型随机试验研究孕期阿司匹林剂量。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: It is unclear whether a higher dose (150-160 mg) or a lower dose (75 mg) of aspirin should be used to prevent preeclampsia.
OBJECTIVES: To compare the risk of preeclampsia and bleeding complications between women using 150 to 160 mg of aspirin and those using 75 mg of aspirin for preeclampsia prevention.
DESIGN, SETTING, AND PARTICIPANTS: This nationwide cohort study included 13 828 women giving birth at 22 weeks' gestation or later in Sweden between January 2017 and December 2020 who used low dose aspirin (75-160 mg) during pregnancy. Data were analyzed from October to November 2023.
EXPOSURE: The use of 150 to 160 mg or 75 mg of aspirin in pregnancy.
MAIN OUTCOME AND MEASURES: The main outcome was a preeclampsia diagnosis recorded in the maternal birth record at the time of hospital discharge. The main safety outcome was postpartum hemorrhage, defined as bleeding more than 1000 mL after delivery. Relative risks (RRs) and 95% CIs were estimated using a doubly robust inverse probability-weighted regression adjustment model controlling for background characteristics.
RESULTS: In the total cohort of 13 828 women, the mean (SD) age was 33.0 (5.5) years and 3003 women (21.7%) were nulliparous. Of the women, 4687 (33.9%) were prescribed 150 to 160 mg of aspirin, and 9141 (66.1%) were prescribed 75 mg of aspirin. A total of 10 635 women (76.9%) had at least 2 dispensed prescriptions of low-dose aspirin. Among women using 150 to 160 mg of aspirin, 443 (9.5%) developed preeclampsia compared with 812 (8.9%) of those using 75 mg of aspirin (adjusted RR [aRR], 1.07; 95% CI, 0.93-1.24). Additionally, the risk of postpartum hemorrhage between the groups was similar, with 326 women (6.9%) using 150 to 160 mg of aspirin experiencing a postpartum hemorrhage compared with 581 (6.4%) in the 75-mg group (aRR, 1.08; 95% CI, 0.90-1.30).
CONCLUSIONS AND RELEVANCE: In this cohort study of 13 828 women, no difference was found in preeclampsia incidence or bleeding complications between those using 150 to 160 mg of aspirin vs 75 mg of aspirin during pregnancy for preeclampsia prevention. These findings suggest that either dose may be a reasonable choice when using aspirin to prevent preeclampsia. However, large randomized trials investigating aspirin dose in pregnancy are still needed.
参考来源
- Kupka E, Hesselman S, Gunnarsdóttir J, et al. Prophylactic Aspirin Dose and Preeclampsia. JAMA Netw Open. 2025. PMID: 39899294. doi:10.1001/jamanetworkopen.2024.57828
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。